NOV03 prevents excessive tear evaporation and has the ability to restores tear film balance. The investigational drug has a unique mode-of-action: It stabilizes the lipid layer for hours to protect the tear film and has the ability to penetrate the Meibomian glands.
In the recent Phase 3 study (GOBI), NOV03 met all primary and secondary endpoints, including improvement of :
Results demonstrated in the GOBI trial confirm all efficacy and safety results from the previous Phase 2 SEECASE trial.
The Phase 3 program for NOV03 includes the successful GOBI trial from 597 participants, an completely enrolled second Phase 3, multi-center, randomized, doublemasked, saline-controlled trial (MOHAVE) with a total of 622 participants and an ongoing multi-center, open-label, single-arm 12-month safety extension trial (KALAHARI).
The ongoing phase 3 study in China started in February 2021. The submission of the IND in China was the result of an effective collaboration between the development teams at Hengrui Medicine and Novaliq.
Our products target key drivers of the disease and have constantly demonstrated significant improvement in sign and symptoms of dry eye in clinical trials.
© Novaliq GmbH | Realization: formativ.net GmbH